The stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
The study, conducted by a team of researchers led by Nathan Harrison, a behavioral scientist and PhD student from Flinders University, in Australia, aimed to identify and synthesize existing interventions to combat stigma associated with lung cancer and smoking-related respiratory diseases, including chronic obstructive pulmonary disease .
In 2021, IASLC published the IASLC Language Guide detailing preferred language and phrasing for all oral and written communications, including presentations at IASLC conferences. Feldman's analysis of 519 presentations at the IASLC World Conference on Lung Cancer 2022 in Vienna found that 177 presentations discussed smoking status, 77 presenters used non-stigmatizing language, while 100 presenters used the stigmatizing term "smoker.
As denormalization strategies have been central to population-level tobacco control responses that discourage smoking, evidence suggests that stigma around lung cancer and respiratory diseases may be on the rise. To address this issue, developing stigma-reducing interventions for affected individuals has been identified as a priority.
Related StoriesThe researchers searched four electronic databases , focusing on lung cancer, COPD, and stigma-related terms, for relevant records published up to December 2022. Eligible studies described an intervention designed to reduce externalized or internalized stigma associated with smoking-related respiratory disease and were assessed using JBI critical appraisal tools as appropriate for the varied study designs.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Study provides new hope for patients with stage III EGFR-mutant non-small cell lung cancerThe immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.
Læs mere »
Stigmatization of smoking-related diseases is a barrier to care, and the problem may be on the riseThe stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Læs mere »